Human Genome

Human Genome News

  • Chevron Defies California On Carbon Emissions

    Chevron Corp. helped write the first-in-the-nation rule ordering reduced carbon emissions from cars and trucks. Its biofuels chief spoke at the ceremony where California Governor Arnold Schwarzenegger signed the executive order in 2007, the same year the oil company pledged to develop a gasoline replacement from wood.

  • Living-Fossil Fish’s Genome Gives Clues of Landlubbers

    The fish known as a living fossil for its close resemblance to ancient predecessors had its genome sequenced by scientists who say it offers clues to how animal ancestors crawled out of the sea.

  • Wachtell, WilmerHale, Cravath, Skadden: Business of Law

    Wachtell, Lipton, Rosen & Katz and Wilmer Cutler Pickering Hale & Dorr LLP acted as legal advisers to Thermo Fisher Scientific Inc., the second-biggest maker of life-sciences equipment by market value, which agreed to buy Life Technologies Corp. for $13.6 billion in cash in a deal that expands its reach in medical testing.

  • High Court Justices Seek Compromise in Gene-Patent Case

    A U.S. Supreme Court clash over the patenting of human genes left several justices searching for a middle ground in a case with the potential to redefine rights in the biotechnology and agricultural industries.

  • Biotech Industry at Stake in Human Gene Patent Decision

    For 30 years, biotechnology innovators have secured thousands of U.S. patents on genes, defining the legal rights to medical and agricultural products worth hundreds of billions of dollars.

  • Obama $100 Million Plan to Map Brain Starting in 2014

    President Barack Obama announced a U.S. campaign that may lead to new treatments for some of the least understood brain disorders, benefiting efforts by Pfizer Inc., Roche Holding AG and Eli Lilly & Co.

  • Obama $100 Million Plan to Map Brain Starting in 2014

    President Barack Obama announced a campaign that could lead to new treatments for some of the least understood brain disorders, benefiting efforts by Pfizer Inc., Roche Holding AG and Eli Lilly & Co.

  • Patients Should Be Told of Unexpected Gene Test Results

    Patients who undergo broad DNA testing to explain a specific medical condition also should be told about chance findings that indicate risk for other serious diseases, a group of genetic specialists said.

  • Theravance Seen Luring Glaxo Bid as Drugs Near FDA Nod: Real M&A

    Theravance Inc.’s projected U.S. approval for its respiratory drugs is fueling speculation of an almost threefold revenue surge and a takeover bid from partner GlaxoSmithKline Plc.

  • Human Genome Returning 13% With Bet on Glaxo Sweetener

    Human Genome Sciences Inc. investors betting on a sweetened bid from GlaxoSmithKline Plc stand to reap a 13 percent return, even as their expectations of securing America’s biggest price increase diminish.

Advertisement
Sponsored Links
Advertisement
Curation software by Lingospot